Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:
“ACLC24, IASLC Asia.
Oral Abstract Session 1.
Chairs: Duan Jianchun and Xiuhao Zhang.
Speaker: Si-Yang Liu.
CTONG1804: Vβ24-1Jβ2-1+/Vβ29-1Jβ2-7+ T Cells Associated Favorable Outcomes for stage II/III NSCLC patients with Neoad Nivo.”
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital. He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.
